Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
FibroGen ( (FGEN) ) has issued an update.
On August 29, 2025, FibroGen completed the sale of its subsidiary, FibroGen China, to AstraZeneca for approximately $220 million. This transaction, which includes $85 million in enterprise value and $135 million in net cash, strengthens FibroGen’s financial position and extends its cash runway into 2028. The sale allows FibroGen to repay its term loan to Morgan Stanley Tactical Value and focus on advancing its clinical programs, including the Phase 2 trial of FG-3246 and the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS. The sale also reinforces FibroGen’s partnership with AstraZeneca, its long-time commercialization partner for roxadustat in China and South Korea.
The most recent analyst rating on (FGEN) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its weak financial performance, which poses significant risks. However, positive technical indicators and strategic corporate events provide some optimism. The earnings call also highlighted potential improvements in cash flow and strategic focus, but ongoing financial challenges remain a concern.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia. Its key product, roxadustat, is approved in several regions for treating anemia in chronic kidney disease patients. The company is also advancing FG-3246, a first-in-class antibody-drug conjugate for metastatic castration-resistant prostate cancer, along with its companion diagnostic FG-3180.
Average Trading Volume: 55,713
Technical Sentiment Signal: Sell
Current Market Cap: $47.84M
See more insights into FGEN stock on TipRanks’ Stock Analysis page.